ArticleMethods in molecular biology (Clifton, N.J.)2025
Knockdown of Gene Expression Following Activation of the NMD Pathway Using Splice-Switching Oligonucleotides.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antisense oligonucleotides (ASOs) are commonly used to induce transient changes in gene expression and do not result in mutagenic effects at the DNA level. In this chapter, we describe a novel gene silencing approach using splice-switching oligonucleotides (SSOs) capable of hybridizing at a splice site to induce exon skipping. This strategy is based on the elimination of an exon whose nucleotide length is not a multiple of 3. In this way, exon skipping induces a frameshift in the reading frame and the appearance of a premature termination codon (PTC) on the alternative transcript. After detection of the PTC, alternative transcripts are degraded by the NMD pathway. Here, we present the steps involved in the SSO design, cell treatment, and assessment of gene silencing. We provide evidence for efficient knockdown of Enhancer of Zeste Homolog 2 (EZH2) expression in lymphoid cells.
Indexed as
Identifiers
40699433What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.